ASX:PAA PharmAust (PAA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About PharmAust Stock (ASX:PAA) 30 days 90 days 365 days Advanced Chart Get PharmAust alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.27 million shsAverage VolumeN/AMarket CapitalizationA$111.93 millionP/E RatioN/ADividend Yield3.88%Price TargetN/AConsensus RatingN/A Company Overview PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia. Read More Receive PAA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmAust and its competitors with MarketBeat's FREE daily newsletter. Email Address PAA Stock News HeadlinesNeurizon Therapeutics Reports Significant Loss Amidst Strategic ShiftFebruary 16, 2025 | tipranks.com‘Outstanding milestone’: FDA grants PharmAust orphan drug designation for monepantelMay 20, 2024 | msn.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. July 6 at 2:00 AM | Altimetry (Ad)PharmAust inks approval from Macquarie University for Open-Label MND extension studyApril 10, 2024 | msn.comWe Think PharmAust (ASX:PAA) Can Afford To Drive Business GrowthMarch 27, 2024 | finance.yahoo.comClosing Bell: ASX a little lower after hosting a Big 4 bank midweek spankMarch 14, 2024 | msn.comPharmAust files groundbreaking MND/ALS clinical data with the FDAMarch 14, 2024 | msn.comIf you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 nowMarch 13, 2024 | fool.com.auSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryTransportation Current SymbolASX:PAA CIKN/A Webwww.pharmaust.com Phone61 8 6161 7412FaxN/AEmployees4,100Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$8.90 million Net Margins-896.47% Pretax MarginN/A Return on Equity-86.89% Return on Assets-42.14% Debt Debt-to-Equity RatioN/A Current Ratio12.42 Quick Ratio2.24 Sales & Book Value Annual SalesA$3.71 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.50 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares486,640,000Free FloatN/AMarket CapA$111.93 million OptionableNot Optionable Beta1.55 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (ASX:PAA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTHIS IS IT. Your FINAL CHANCE. At midnight, our 82% OFF July 4th deal disappears FOREVER. The countdown ...Investors Alley | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmAust Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmAust With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.